About BEKhealth
BEKhealth helps health care organizations decide which clinical studies fit their patients and find people who may qualify. Its software processes electronic medical records, including free-text notes, and maps their contents to a study’s eligibility rules. The company provides cloud tools for trial assessment, recruitment and care coordination.
The company has a Chapel Hill, North Carolina address, and David Levin is chief executive officer. Galileo launched with a library of 24 million medical terms for researchers.
Funding Rounds (SEC Form D)
| First sale | Filed with SEC | Amount sold | Investors | Avg. check | Terms | Filing |
|---|---|---|---|---|---|---|
| Oct 8, 2026 | Oct 21, 2026 | $5,000,000of $6.0M target | 12 | $416K | EquityRule 506(b) | Form D ↗ |
| Sep 6, 2024 | Sep 17, 2024 | $3,597,455of $4.6M target | 13 | $276K | EquityRule 506(b) | Form D ↗ |
| Nov 3, 2023 | Nov 13, 2023 | $1,609,060of $3.0M target | 5 | $321K | EquityRule 506(b) | Form D ↗ |
| Feb 13, 2023 | Feb 24, 2023 | $5,474,069of $7.3M target | 14 | $391K | EquityRule 506(b) | Form D ↗ |
| Jun 2, 2021 | Jun 16, 2021 | $4,573,580of $4.7M target | 16 | $285K | EquityRule 506(b) | Form D ↗ |
| Total, five offerings | $20,254,164 | |||||
First sale is the date the first investor in the offering committed to invest. Companies must file Form D within 15 days of that date, so filing dates run later.
Why Investors Backed BEKhealth
BEKhealth sells clinical-research software to health care organizations. Its tools automate work that otherwise involves complex searches and cross-checking. The platform also supports decentralized studies intended to reach patients across locations.
The problem it targets
Health care organizations receive frequent requests to conduct studies, but determining whether each plan fits their patients takes substantial work. Staff may need to build complex searches and compare several data sources. Records can also use language that differs from trial plans. These barriers slow feasibility reviews and can obscure eligible candidates across multiple locations.
What the product does
Galileo gives users one view of patients across practices and satellite locations. It evaluates complete study plans rather than isolated criteria. The tool can reduce feasibility work from weeks to about an hour. Researchers can also examine geographic and demographic details from a central location.
Progress so far
BEKhealth introduced Galileo in October 2021, when founder Jason Baumgartner was chief executive officer. In November 2022, Curebase announced a partnership with BEKhealth for decentralized trials. BEKhealth planned to run Curebase study plans across its network and return patients meeting at least 90% of the criteria. The work included oncology and sites new to decentralized trials.
Who backs it
Boston Millennia Partners includes BEKHealth in its health care portfolio. The investment firm describes a unified AI analytics platform with cloud tools for feasibility, recruitment and care coordination.
We wrote this summary from public statements by BEKhealth and its investors. It is not investment advice.
Leadership Team
Executive officers and directors listed on BEKhealth's Form D filed Oct 21, 2026.
Earlier filings also listed Joshua Ransom (executive officer, last listed Sep 2024), Christian Burns (director, last listed Sep 2024), Bobby Bahram (director, last listed Sep 2024), Jason Baumgartner (director, last listed Nov 2023), Devin Carty (director, last listed Nov 2023) and Andrew Schwab (director, last listed Nov 2023).